OHSU

Current Research Studies

Without research, new treatments for epilepsy and other seizure disorders would not be possible. The OHSU Comprehensive Epilepsy Center is known around the United States for its innovative research to improve the diagnosis and treatment of epilepsy and other conditions that cause seizures.

By participating in one of our research studies, you can try the latest treatments before they are available to the general public. You also help others with epilepsy or seizure disorders by helping researchers discover new treatments.

Our research includes:

  • Testing the vagus nerve stimulator (VNS), an effective treatment for seizure disorders now used by thousands of patients worldwide.
  • Studying other advanced forms of electrical stimulation to stop seizures.
  • Clinical trials of medications now being used for epilepsy.
  • Studying the effects of common epilepsy drugs on memory.
  • Developing new and better ways to use magnetic resonance imaging (MRI) to find brain abnormalities that cause epilepsy. Improving MRI leads to safer, more effective brain surgery for epilepsy. This can help some people live without seizures.
  • Basic (laboratory) research to understand what causes seizures.

The OHSU Comprehensive Epilepsy Center has several clinical trials (research studies) going on. For more information, please call our study coordinator at 503 494-9633.

 

Current Research Studies

Recruiting

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters
ARTEMIS-1: Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray-1

 

Not Currently Recruiting

 

TITLE: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters
ARTEMIS-1 Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray-1

Principal Investigator:
David Spencer, M.D.      

Co-Investigators:           
James Cereghino, M.D.
Paul Motika, M.D. 

Criteria for recruitment:
We’re recruiting patients who have epilepsy and who have seizure clusters.  A caregiver must be identified to participate with the patient throughout the study, which may last up-to 1 year.

 

TITLE: A prospective, open-label study of the structure and function of the retina in adult patients with refractory complex partial seizures treated with vigabatrin (Sabril®)

Principal Investigator:
Martin Salinsky, M.D.    

Co-Investigators:
David Spencer, M.D. 
Mark Pennesi, M.D., Ph.D.
Paul Motika, M.D. 

Criteria for recruitment:
We’re recruiting patients with Refractory Complex Partial Seizures (CPS) who have been recommended vigabatrin (Sabril) by their treating physician. Study duration may last up-to 15 months.  Participants are reimbursed $110/visit to offset time/travel expenses.

 

TITLE: An open-label, multicenter, follow-up trial to evaluate the long-term safety and efficacy of brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 200 mg / day in subjects aged 16 years or older suffering from epilepsy (Note:  OHSU will only be enrolling subjects who are at least 18 years old.)

Principal Investigator:
James Cereghino, M.D.

Co-Investigators:
Martin Salinsky, M.D.         
David Spencer, M.D. 

 

TITLE: RNS® System Long-Term Treatment Clinical Investigation

Principal Investigator:
James Cereghino, M.D.   

Co-Investigators:           
Martin Salinsky, M.D. 
David Spencer, M.D. 

 

TITLE: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters (ARTEMIS-1 Extention study)

Principal Investigator:
David Spencer, M.D.

Co-Investigators:   
James Cereghino, M.D.
Paul Motika, M.D.